Solomon Moshkevich Sells 4,858 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 4,858 shares of Natera stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total value of $809,294.22. Following the transaction, the insider now directly owns 114,912 shares in the company, valued at $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $141,379.16.
• On Tuesday, October 22nd, Solomon Moshkevich sold 256 shares of Natera stock. The shares were sold at an average price of $120.07, for a total value of $30,737.92.

Natera Stock Performance

NTRA opened at $166.45 on Friday. Natera, Inc. has a 1-year low of $57.22 and a 1-year high of $175.63. The company has a market cap of $21.97 billion, a price-to-earnings ratio of -94.57 and a beta of 1.63. The company’s fifty day moving average price is $143.28 and its two-hundred day moving average price is $124.06. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.95) EPS. On average, analysts expect that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Chartwell Investment Partners LLC raised its position in Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after buying an additional 11,362 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new stake in shares of Natera in the 2nd quarter worth $478,000. Cerity Partners LLC raised its holdings in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of Natera by 50.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company’s stock valued at $1,475,000 after purchasing an additional 4,575 shares in the last quarter. Finally, Jag Capital Management LLC boosted its holdings in Natera by 8.8% during the third quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company’s stock worth $22,291,000 after purchasing an additional 14,159 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. upped their price target on shares of Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. TD Cowen raised their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Sanford C. Bernstein boosted their price target on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.